Gefitinib (ZD1839): Therapy in selected patients with non-small cell lung cancer (NSCLC)?

This publication has 44 references indexed in Scilit:

• Polymorphisms, Mutations, and Amplification of the EGFR Gene in Non-Small Cell Lung Cancers
  PLOS Medicine, 2007
• Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib
  Clinical Cancer Research, 2006
• Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
  New England Journal of Medicine, 2005
• Is there a relationship between c-erbB-1 and c-erbB-2 amplification and protein overexpression in NSCLC?
  Lung Cancer, 2005
• Predicting Sensitivity of Non-Small-Cell Lung Cancer to Gefitinib: Is There a Role for P-Akt?
  JNCI: Journal of the National Cancer Institute, 2004
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
  Science, 2004
• Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
  New England Journal of Medicine, 2004
• Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer
  Journal of Clinical Oncology, 2004
• O-241 Clinical, pathologic, and molecular characteristics of NSCLC patients sensitive to gefitinib
  Lung Cancer, 2003
• New Guidelines to Evaluate the Response to Treatment in Solid Tumors
  JNCI: Journal of the National Cancer Institute, 2000